Recombinant Human Bone morphogenetic protein receptor type-1A (BMPR1A), Truncated

Uniprot Id

P36894

Target Species

Human

Target Name

BMPR1A

Target Full Name

Bone morphogenetic protein receptor type-1A

Target Function

On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively regulates chondrocyte differentiation through GDF5 interaction. Mediates induction of adipogenesis by GDF6.

Target Involvement

Juvenile polyposis syndrome (JPS); Polyposis syndrome, mixed hereditary 2 (HMPS2)

Target Subcellular Location

Cell membrane; Single-pass type I membrane protein. Cell surface.

Target Protein Families

Protein kinase superfamily, TKL Ser/Thr protein kinase family, TGFB receptor subfamily

Target Tissue Specificity

Highly expressed in skeletal muscle.

Target Research Area

Cardiovascular

Target Synonyms

10q23del; Activin A receptor type II like kinase 3; Activin receptor like kinase 3; Activin receptor-like kinase 3; ACVRLK 3; ACVRLK3; ALK 3; ALK-3; ALK3; BMP type-1A receptor; BMPR 1A; Bmpr; BMPR-1A; Bmpr1a; BMR1A_HUMAN; Bone morphogenetic protein receptor type IA; Bone morphogenetic protein receptor type IA precursor; Bone morphogenetic protein receptor type-1A; BR 1a; BR1a; CD 292; CD292; CD292 antigen; EC 2.7.11.30; Serine threonine protein kinase receptor R5; Serine threonine protein kinase receptor R5 precursor; Serine/threonine-protein kinase receptor R5; SKR 5; SKR5; zBMPR IA; zBMPRIA

Target Background

The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding.